KR102718253B1 - 신규한 하이드록시에스테르 유도체, 이들의 제조 방법 및 이들을 함유하는 약학적 조성물 - Google Patents

신규한 하이드록시에스테르 유도체, 이들의 제조 방법 및 이들을 함유하는 약학적 조성물 Download PDF

Info

Publication number
KR102718253B1
KR102718253B1 KR1020187002033A KR20187002033A KR102718253B1 KR 102718253 B1 KR102718253 B1 KR 102718253B1 KR 1020187002033 A KR1020187002033 A KR 1020187002033A KR 20187002033 A KR20187002033 A KR 20187002033A KR 102718253 B1 KR102718253 B1 KR 102718253B1
Authority
KR
South Korea
Prior art keywords
phenyl
pyrimidin
cancer
formula
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187002033A
Other languages
English (en)
Korean (ko)
Other versions
KR20180019223A (ko
Inventor
졸탄 슐라비크
안드라스 코치
마이아 찬리온
디디에 데말스
올리비에 제네스테
제임스 에드워드 폴 데이비슨
제임스 브룩 머레이
사볼츠 시포스
아틸라 파찰
발라즈 발린트
Original Assignee
르 라보레또레 쎄르비에르
베르날리스 (알 앤드 디) 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 르 라보레또레 쎄르비에르, 베르날리스 (알 앤드 디) 리미티드 filed Critical 르 라보레또레 쎄르비에르
Publication of KR20180019223A publication Critical patent/KR20180019223A/ko
Application granted granted Critical
Publication of KR102718253B1 publication Critical patent/KR102718253B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
KR1020187002033A 2015-06-23 2016-06-22 신규한 하이드록시에스테르 유도체, 이들의 제조 방법 및 이들을 함유하는 약학적 조성물 Active KR102718253B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1555752A FR3037957B1 (fr) 2015-06-23 2015-06-23 Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR1555752 2015-06-23
PCT/EP2016/064433 WO2016207225A1 (en) 2015-06-23 2016-06-22 New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
KR20180019223A KR20180019223A (ko) 2018-02-23
KR102718253B1 true KR102718253B1 (ko) 2024-10-16

Family

ID=54608634

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187002033A Active KR102718253B1 (ko) 2015-06-23 2016-06-22 신규한 하이드록시에스테르 유도체, 이들의 제조 방법 및 이들을 함유하는 약학적 조성물

Country Status (43)

Country Link
US (2) US10227358B2 (enExample)
EP (1) EP3313851B1 (enExample)
JP (1) JP6741697B2 (enExample)
KR (1) KR102718253B1 (enExample)
CN (1) CN107709333B (enExample)
AR (1) AR105103A1 (enExample)
AU (1) AU2016282836B2 (enExample)
BR (1) BR112017027414B1 (enExample)
CA (1) CA2990088C (enExample)
CL (1) CL2017003258A1 (enExample)
CO (1) CO2017012786A2 (enExample)
CR (1) CR20170564A (enExample)
CU (1) CU20170160A7 (enExample)
CY (1) CY1122542T1 (enExample)
DK (1) DK3313851T3 (enExample)
EA (1) EA033266B1 (enExample)
EC (1) ECSP17081744A (enExample)
ES (1) ES2759480T3 (enExample)
FR (1) FR3037957B1 (enExample)
GE (1) GEP20207074B (enExample)
HK (1) HK1249506A1 (enExample)
HR (1) HRP20200107T1 (enExample)
HU (1) HUE047889T2 (enExample)
IL (1) IL256270A (enExample)
JO (1) JO3675B1 (enExample)
MA (1) MA42239B1 (enExample)
MD (1) MD3313851T2 (enExample)
MX (1) MX372716B (enExample)
MY (1) MY190561A (enExample)
PE (1) PE20180742A1 (enExample)
PH (1) PH12017502246A1 (enExample)
PL (1) PL3313851T3 (enExample)
PT (1) PT3313851T (enExample)
RS (1) RS59904B1 (enExample)
RU (1) RU2734418C2 (enExample)
SI (1) SI3313851T1 (enExample)
SV (1) SV2017005587A (enExample)
TN (1) TN2017000511A1 (enExample)
TW (1) TWI604844B (enExample)
UA (1) UA122228C2 (enExample)
UY (1) UY36736A (enExample)
WO (1) WO2016207225A1 (enExample)
ZA (1) ZA201708460B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2017300738A1 (en) 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
WO2018126898A1 (zh) * 2017-01-05 2018-07-12 河南美泰宝生物制药有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
GEP20227372B (en) * 2017-01-06 2022-04-25 Novartis Ag Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
ES2971466T3 (es) * 2017-06-22 2024-06-05 Servier Lab Combinación de un inhibidor de Mcl-1 y un tratamiento estándar de atención para cánceres hematológicos, usos y composiciones farmacéuticas de la misma
SG10202106345VA (en) 2017-08-15 2021-07-29 Abbvie Inc Macrocyclic mcl-1 inhibitors and methods of use
BR112020003163A2 (pt) * 2017-08-15 2020-09-15 AbbVie Deutschland GmbH & Co. KG inibidores macrocíclicos de mcl-1 e métodos de uso
CN111372936B (zh) * 2017-11-23 2022-12-02 北京赛林泰医药技术有限公司 Mcl-1选择性抑制剂及其制备和用途
CN108424417B (zh) * 2017-12-21 2019-09-20 河南真实生物科技有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
CN110964034B (zh) * 2018-09-29 2022-04-12 江苏恒瑞医药股份有限公司 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
TWI849001B (zh) 2018-11-14 2024-07-21 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合,其用途及醫藥組合物
CN111187277B (zh) * 2018-11-14 2022-04-12 江苏恒瑞医药股份有限公司 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
LT3891156T (lt) * 2018-12-06 2023-12-27 Les Laboratoires Servier Tienopirimidino, kaip mcl-1 inhibitoriaus, naujos kristalinės formos
UY38700A (es) 2019-05-20 2020-12-31 Novartis Ag Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
TW202114682A (zh) 2019-06-17 2021-04-16 法商施維雅藥廠 Mcl-1抑制劑與乳癌標準療法之組合,其用途及醫藥組合物
CN114746428B (zh) * 2019-10-03 2025-05-16 加利福尼亚技术学院 Mcl1抑制剂及其应用
US20240042051A1 (en) 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2022216946A1 (en) * 2021-04-07 2022-10-13 California Institute Of Technology Mcl1 inhibitors and uses thereof
WO2022261310A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
CN117651554A (zh) 2021-06-11 2024-03-05 吉利德科学公司 Mcl-1抑制剂与抗癌剂的组合
CN113651663B (zh) * 2021-08-20 2024-03-29 浙大宁波理工学院 一种氘代芳香羰基类化合物的制备方法
WO2023057484A1 (en) 2021-10-06 2023-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗il-1rap結合結構域及其抗體-藥物偶聯物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464667A (zh) 2010-11-03 2012-05-23 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
WO2013072694A1 (en) 2011-11-15 2013-05-23 Xention Limited Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
EP1675861B1 (en) * 2003-08-29 2015-12-23 Vernalis (R&D) Ltd. Pyrimidothiophene compounds
UA100262C2 (uk) * 2008-03-05 2012-12-10 Метилген Інк. Інгібітори активності протеїнтирозинкінази
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464667A (zh) 2010-11-03 2012-05-23 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
WO2013072694A1 (en) 2011-11-15 2013-05-23 Xention Limited Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors

Also Published As

Publication number Publication date
MX372716B (es) 2020-05-28
PL3313851T3 (pl) 2020-05-18
PT3313851T (pt) 2020-01-06
MY190561A (en) 2022-04-27
SI3313851T1 (sl) 2020-03-31
RU2018102365A3 (enExample) 2019-09-23
PH12017502246B1 (en) 2018-05-28
UA122228C2 (uk) 2020-10-12
HK1254657A1 (en) 2019-07-26
CN107709333B (zh) 2021-01-01
RS59904B1 (sr) 2020-03-31
RU2018102365A (ru) 2019-07-23
SV2017005587A (es) 2018-04-11
US20190161496A1 (en) 2019-05-30
US20180170947A1 (en) 2018-06-21
CU20170160A7 (es) 2018-05-08
EA201890125A1 (ru) 2018-06-29
CO2017012786A2 (es) 2018-04-10
PH12017502246A1 (en) 2018-05-28
PE20180742A1 (es) 2018-04-27
UY36736A (es) 2016-12-30
AU2016282836B2 (en) 2020-07-09
MD3313851T2 (ro) 2020-02-29
TWI604844B (zh) 2017-11-11
HUE047889T2 (hu) 2020-05-28
GEP20207074B (en) 2020-03-10
AR105103A1 (es) 2017-09-06
AU2016282836A1 (en) 2018-01-18
CR20170564A (es) 2018-02-20
CL2017003258A1 (es) 2018-06-01
ES2759480T3 (es) 2020-05-11
IL256270A (en) 2018-02-28
JO3675B1 (ar) 2020-08-27
US10711010B2 (en) 2020-07-14
CA2990088A1 (en) 2016-12-29
ZA201708460B (en) 2021-06-30
CN107709333A (zh) 2018-02-16
CA2990088C (en) 2021-04-13
BR112017027414B1 (pt) 2023-12-19
KR20180019223A (ko) 2018-02-23
BR112017027414A2 (pt) 2018-08-28
FR3037957A1 (enExample) 2016-12-30
EA033266B1 (ru) 2019-09-30
WO2016207225A1 (en) 2016-12-29
DK3313851T3 (da) 2020-01-27
NZ738455A (en) 2024-03-22
EP3313851B1 (en) 2019-11-06
JP6741697B2 (ja) 2020-08-19
CY1122542T1 (el) 2021-01-27
ECSP17081744A (es) 2018-02-28
FR3037957B1 (fr) 2019-01-25
EP3313851A1 (en) 2018-05-02
TN2017000511A1 (en) 2019-04-12
TW201709911A (zh) 2017-03-16
RU2734418C2 (ru) 2020-10-16
US10227358B2 (en) 2019-03-12
MX2017016997A (es) 2018-09-07
MA42239B1 (fr) 2020-02-28
HRP20200107T1 (hr) 2020-04-03
JP2018522855A (ja) 2018-08-16
HK1249506A1 (zh) 2018-11-02

Similar Documents

Publication Publication Date Title
KR102718253B1 (ko) 신규한 하이드록시에스테르 유도체, 이들의 제조 방법 및 이들을 함유하는 약학적 조성물
KR102805983B1 (ko) 신규 암모늄 유도체, 이의 제조 방법 및 이를 함유하는 약학적 조성물
KR102620905B1 (ko) 신규한 아미노산 유도체, 이의 제조방법, 및 이를 함유한 약제 조성물
JP6773695B2 (ja) 新規なヒドロキシ酸誘導体、その製造方法、及びそれを含有する医薬組成物
HK1254657B (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
OA18889A (en) New Hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
HK1259781A1 (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
HK40000743B (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
HK40000743A (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210603

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230426

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231021

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240416

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20231021

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20230426

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20240716

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20240723

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241011

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241011

End annual number: 3

Start annual number: 1

PG1601 Publication of registration